T
Torben Plesner
Researcher at University of Southern Denmark
Publications - 205
Citations - 11134
Torben Plesner is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Daratumumab & Multiple myeloma. The author has an hindex of 45, co-authored 186 publications receiving 9295 citations. Previous affiliations of Torben Plesner include University of Copenhagen & Finsen Laboratory.
Papers
More filters
Journal ArticleDOI
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Torben Plesner,Simon J. Harrison,Hang Quach,Cindy Lee,Adam Bryant,Annette Juul Vangsted,Jane Estell,Michel Delforge,Fritz Offner,Patrick J Twomey,Voleak Choeurng,Junyi Li,Robert L. Hendricks,Shannon M. Ruppert,Teiko Sumiyoshi,K Miller,Eunpi Cho,Fredrik Schjesvold +17 more
TL;DR: In this paper , an anti-BCMA/CD16a bispecific antibody (RO7297089) was administered weekly by intravenous infusion to patients with relapsed/refractory multiple myeloma.
Journal ArticleDOI
Subcellular localization of urokinase-type plasminogen activator and its receptor on normal and PNH-affected neutrophils
Trine L. Pedersen,Lars Kjeldsen,Torben Plesner,Henrik Sengeløv,N. Rorregaard,Ebbe Rønne,Jan Grøndahl-Hansen,Keld Danø,Niels Ebbe Hansen +8 more
Journal ArticleDOI
Expression of an antigen defined by a monoclonal antibody (SA‐1) on normal and malignant cells
Søren Avnstrøm,Torben Plesner,Elisabeth Ralfkier,Michael Wilken,James D. Griffin,Nis. I. Nissen +5 more
TL;DR: The antibody was derived from the fusion of the X-63 myeloma cell-line with splenocytes from a mouse immunized with human acute megakaryoblastic leukaemia cells and reacted with blast cells from 65% of patients with AML without correlation to morphologic classification.
Journal Article
The CLL2 study: preliminary results of flow cytometry immunophenotyping in the first 500 patients.
Christian H. Geisler,Larsen Jk,Andersen E,H. Birgens,Christensen Be,Drivsholm A,Hansen Mm,Peter Hokland,Jensen Kb,Torben Plesner +9 more
TL;DR: In this preliminary phenotype analysis of the first 500 patients in the CLL2 study, no important prognostic subgroups were detected, although this might be due to the still short observation time (median observation time 532 days).
Journal Article
Quality of life with melphalan/prednisone plus either thalidomide (MPT-T) or lenalidomide (MPR-R) in non-transplant eligible newly diagnosed multiple myeloma; Results of the Hovon87/NMSG18 study
Claudia A.M. Stege,L. Kongsgaard Nielsen,Birgit I. Witte,B. van der Holt,U. H. Mellqvist,Morten Salomo,Gerard M. J. Bos,Moshe Levin,Heleen Visser-Wisselaar,Markus Hansson,A.W.G. van der Velden,Wendy Deenik,Astrid Gruber,Jules L.L.M. Coenen,Torben Plesner,Saskia K. Klein,B.C. Tanis,Damian L. Szatkowski,Rolf Brouwer,Matthijs Westerman,Rineke B. L. Leys,Harm Sinnige,E. Haukas,K. van der Hem,Marc Durian,V. Mattijssen,Peter Gimsing,N. van de Donk,Marian Stevens-Kroef,Pieter Sonneveld,Anders Waage,Sonja Zweegman,Niels Abildgaard +32 more
TL;DR: Evaluating the HRQoL results of the HOVON87/NMSG18 study found both treatment with MPT-T and MPR-R controlled pain and resulted in an improvement in global QoL as compared to baseline after 9ID and during maintenance therapy.